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and non-users. The change in creatine kinase from pre to 
peak was significantly higher in OCP users compared to 
non-users (962 ± 968 and 386 ± 474 Ul, respectively, 
p = 0.016). There were no other differences in markers of 
muscle damage.
Conclusion Although our findings suggest that, when com-
pared to non-users, the OCP may augment the creatine 
kinase response following eccentric exercise, it does not 
increase the susceptibility to any other markers of muscle 
damage.
Keywords Exercise-induced muscle damage · Oral 
contraceptive pill · Tendon properties
Abbreviations
ANOVA  Analysis of variance
CK  Creatine kinase
EIMD  Exercise-induced muscle damage
MVEKE  Maximal voluntary eccentric knee contractions
MVCKE  Maximal voluntary isometric knee extension
MVCKF  Maximal voluntary isometric knee flexions
OCP  Oral contraceptive pill
ΔCKpeak  The increase from pre to peak CK over 168 h
VL  Vastus lateralis
VLACSA  Vastus lateralis anatomical cross-sectional area
Introduction
Exercise-induced muscle damage (EIMD) has been shown 
to be lower in females compared to males (Joyce et al. 
2014; Sewright et al. 2008). It has been suggested that this 
attenuated EIMD is due to the direct antioxidant properties 
of oestrogen (Carter et al. 2001). However, an indirect role 
of oestrogen in suppressing EIMD, through altering the 
Abstract 
Purpose Firstly, to establish whether oral contraceptive pill 
(OCP) users are more susceptible to muscle damage com-
pared to non-users, and secondly, to establish whether dif-
ferences can be attributed to differences in patella tendon 
properties.
Methods Nine female OCP users and 9 female non-users 
participated in the investigation. Combining dynamom-
etry, electromyography and ultrasonography, patella tendon 
properties and vastus lateralis architectural properties were 
measured pre and during the first of 6 sets of 12 maximal 
voluntary eccentric knee extensions. Serum oestrogen lev-
els were measured on the 7th day of the pill cycle and the 
14th day of menstrual cycle in OCP users and non-users, 
respectively. Maximal voluntary isometric knee exten-
sion torque loss, creatine kinase and muscle soreness were 
measured 48 h pre-damage, post-damage, and 48, 96 and 
168 h post-damage.
Results Oestrogen levels were significantly lower in 
OCP users compared to non-users (209 ± 115 and 
433 ± 147 pg/ml, respectively, p = 0.004). Proposed deter-
minants of muscle damage, patella tendon stiffness and 
maximal eccentric torque did not differ between OCP users 
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tendon properties in females, has recently been proposed 
(Hicks et al. 2016).
The role of oestrogen in attenuating EIMD has been 
assessed through the manipulation of circulating lev-
els in animals and has been shown to attenuate EIMD in 
both male and female rats (Amelink et al. 1990, 1991; Bär 
et al. 1988). For example, Bär et al. (1988) reported that 
the increase in creatine kinase (CK) post-EIMD, in both 
males and ovariectomised female rats, was suppressed 
by oestrogen supplements prior to EIMD. Alternatively, 
within human studies, oestrogen levels can be manipu-
lated through the use of synthetic hormones [e.g. hormone 
replacement therapy and the oral contraceptive pill (OCP)].
The OCP down regulates oestrogen levels throughout 
the menstrual cycle by altering the hypothalamic–pitui-
tary–ovarian feedback loop, thus inhibiting the peak in 
oestrogen at ovulation (Elliott-Sale et al. 2013; Van Heu-
sden and Fauser 2002). Consequently, women who take 
the OCP have significantly lower levels of circulating 
oestrogen compared to non-users throughout the men-
strual cycle (Bryant et al. 2008; Fleischman et al. 2010). 
Due to the protective properties of oestrogen and the sup-
pressed oestrogen levels in OCP users, it is suggested that 
OCP users are more susceptible to EIMD; however, the 
literature remains inconclusive with evidence supporting 
(Carter et al. 2001; Joyce et al. 2014; Minahan et al. 2015) 
or refuting (Sewright et al. 2008; Thompson et al. 1997) an 
increased susceptibility to EIMD. For example, in support 
of an increased susceptibility to EIMD, 48-h post-maximal 
eccentric leg extensions Joyce et al. (2014), reported sig-
nificantly higher levels of serum CK levels in males and 
female OCP users compared to female non-users. Whereas, 
following maximal eccentric contractions of the elbow 
flexors, Sewright et al. (2008) reported no significant dif-
ference in CK between OCP users and non-users. The dif-
ferences in exercise protocols/exercising muscle groups 
(Chen et al. 2011) and different phases of the menstrual 
cycle/oestrogen levels, make it difficult to determine the 
true role of the OCP on EIMD.
In addition to acting as an antioxidant, oestrogen may 
indirectly attenuate EIMD through altering tendon prop-
erties. Compliant tendons have been evidenced to miti-
gate fascicle lengthening (Hicks et al. 2013) and attenuat-
ing peak forces and torques during eccentric contractions 
(Hoffman et al. 2014; Roberts and Azizi 2010; Roberts and 
Konow 2013). Therefore, it is suggested that lower tendon 
stiffness may act as a mechanical buffer and attenuate lev-
els of EIMD (Hoffman et al. 2014; Roberts and Azizi 2010; 
Roberts and Konow 2013).
High oestrogen levels have been reported to decrease 
tendon stiffness by attenuating the rate of tendon collagen 
synthesis (Hansen et al. 2009a, b). In parallel, IGF-I has an 
anabolic effect on tendon fibroblasts by increasing collagen 
syntheses in a dose-dependent manner (Olesen et al. 2006) 
and hence would be assumed to be associated with higher 
tendon stiffness. Interestingly, oestrogen is associated with 
decreased IGF-I bioavailability (Heald et al. 2005). In other 
words, a lower tendon stiffness would be expected in the 
presence of elevated oestrogen due to the sequestering 
away of IGF. Within OCP users, however, despite lower 
oestrogen levels compared to non-users, it remains unclear, 
with arguments supporting (Bryant et al. 2008) or contest-
ing (Hansen et al. 2013) differences in tendon properties 
between OCP users and non-users. It is possible, however, 
that the aforementioned discrepancies between Bryant et al. 
(2008) and Hansen et al. (2013) findings may be attributed 
to differences in the number of available oestrogen recep-
tors expressed on the Achilles and patella tendon.
Therefore, the aim of the current study was twofold: 
firstly, to establish whether OCP users are more susceptible 
to EIMD compared to non-users and secondly, to establish 
whether any differences in EIMD could be attributed, in 
part, to differences in tendon properties.
Materials and methods
Participants
A total of 18 females were divided into two groups: women 
taking a monophasic OCP (n = 9, 23.4 ± 2.4 years of 
age, 70.0 ± 9.9 kg and 1.70 ± 0.05 m) and eumenorrheic 
women who had never taken the OCP [(non-users) n = 9, 
21.2 ± 1.5 years of age, 63.2 ± 5.6 kg and 1.65 ± 0.09 m]. 
All participants self-reported as being recreationally active 
(undertaking no more than 1 h of “moderate” physical 
activity per week) and did not take part in any structured 
resistance training. All procedures complied with the Dec-
laration of Helsinki World Medical Association (2013) and 
ethical approval was obtained through the local ethics com-
mittee at Manchester Metropolitan University. All women 
reported regular menstrual cycles, documenting an average 
cycle length of 28 ± 1 days. On average the OCP users had 
been taking a combined monophasic OCP, with an ethinyl 
estradiol dosage between 20 and 30 µg for 3 ± 1 years. 
The types of OCP used within the current study are taken 
daily followed by a 7-day pill-free interval. Exclusion cri-
teria included any resistance training undertaken in the 
last 6 months, occupation or lifestyle that required regular 
heavy lifting or carrying, any known muscle disorder, the 
use of dietary supplements (for example, multivitamins), 
and any musculoskeletal injury in the last 3 months. Fur-
ther exclusion criteria included, previous use of any other 
forms of hormone-based contraception, continuous pill 
OCP or mini-OCP users, irregular menstrual cycles [where 
regular cycles were defined as 24–36 days (Cole et al. 
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2009; Landgren et al. 1980)] in the last 12 months, and 
pregnancy in the year preceding inclusion in the current 
study. All inclusion and exclusion criteria were determined 
through participant questionnaire prior to inclusion within 
this investigation.
Testing protocol
Once selected, participants were asked to visit the labora-
tory on five different occasions over 9 days. Non-users 
were tested on the 14th day (self-reported) of the men-
strual cycle to measure oestrogen levels at ovulation 
(Brown 1955; Cole et al. 2009). To reflect the timing of 
ovulation in the non-users and to try and avoid the sec-
ondary peak in oestrogen levels (Legro et al. 2008), OCP 
user’s oestrogen levels were tested on the 7th pill taking 
day (Elliott et al. 2005). The 7th pill taking day is equiva-
lent to the 14th day of the overall pill cycle (7 pill-free 
days plus 7 pill taking days), therefore the measurement 
day will be referred to as the 14th day of the cycle from 
this point forward. To avoid an acute peak in oestrogen 
levels the OCP users were not tested within 2 h of tak-
ing their OCP (Sneader 2005). The design and several 
of the measurement techniques within the current study 
have been reported previously (Hicks et al. 2013). The 
testing sessions were as follows: (1) pre-damage; (2) 
damage (48 h post pre-damage); (3) 48 h; (4) 96 h and 
(5) 168 h post-damage (see Fig. 1). Pre-damage assess-
ments consisted of stature and mass (anthropometric 
measures), patella tendon moment arm, 5–6 ml blood 
sample (for serum CK levels), dynamometer familiarisa-
tion (within pre-damage), morphological and mechanical 
measures of the patella tendon (tendon size and stiffness, 
respectively) and maximal voluntary isometric knee 
extension  (MVCKE) torque measurements at six angles 
[60°, 65°, 70°, 75°, 80° and 90° (full extension = 0°)]. 
Participants performed two practice maximal voluntary 
contractions, at two knee joint angles during the famil-
iarisation session. Stature and mass were measured using 
a wall-mounted stadiometer (Harpenden, Holtain Cry-
mych, UK) and digital scales (Seca model 873, Seca, 
Germany), respectively. The damage session was on the 
14th day of the cycle (pill or menstrual) in OCP users 
and non-users. The damage session consisted of maximal 
voluntary eccentric knee contractions  (MVEKE), 5–6 ml 
venous blood sample (for serum CK and oestrogen lev-
els), rating of muscle soreness and  MVCKE torque meas-
urements. 48, 96 and 168 h testing session consisted of 
5–6 ml blood sample (for serum CK levels), rating of 
muscle soreness, and  MVCKE torque measurements at six 
angles (60°, 65°, 70°, 75°, 80° and 90°).
All tests were carried out in the non-dominant leg. The 
non-dominant leg was defined as the leg that provided 
stability during movements such as kicking a ball. Partic-
ipants were seated in an isokinetic dynamometer (Cybex 
Norm, Cybex International, NY, USA), with a hip angle 
of 85°. To reduce any extraneous movement during maxi-
mal efforts, participants were secured in a seated position 
using inextensible straps secured around the shoulders 
and hips. The isokinetic dynamometer axis of rotation 
was visually aligned with the knee joint’s centre of rota-
tion. During pre-damage, the isokinetic dynamometer 
settings (chair position, distance from the dynamometer, 
dynamometer arm length) and anatomical zero (leg fully 
extended, knee angle 0°) were recorded to ensure accu-
rate repeatability in the following sessions.
MVCKE, CK, muscle soreness
Oestrogen measurement
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Fig. 1  Schematic diagram to illustrate the testing timeline throughout the cycle (pill or menstrual) in OCP users and non-users. MVCKE maximal 
voluntary isometric knee extension, CK creatine kinase, VL vastus lateralis
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Vastus lateralis anatomical cross‑sectional area
The method used to determine vastus lateralis (VL) cross-
sectional area has been reported in detail previously (Hicks 
et al. 2013). In brief, in a supine position, VL anatomical 
cross-sectional area  (VLACSA) was measured using a real-
time B-mode ultrasound (AU5 Harmonic, Esaote Bio-
medica, Genoa, Italy). At 50% of VL muscle length echo-
absorptive markers (Transpore surgical tape, Medisave UK 
Ltd, UK), were placed in parallel at intervals of 30 mm. 
The ultrasound probe (7.5 MHz linear array probe, 38 mm 
wide), was held perpendicular to the VL muscle in the axial 
plane, and moved steadily over the echo-absorptive mark-
ers from the lateral to the medial edge of the muscle. The 
images were recorded in real-time at 25 frames per second 
(Adobe Premier pro Version 6, Adobe Systems Software, 
Ireland). Using video editing software (Adobe Premier 
Elements, version 10), still images were acquired at each 
30 mm interval. The shadows cast by the echo-absorp-
tive markers allowed the neighbouring still images to be 
aligned, thus reconstructing the entire  VLACSA in a single 
image (Adobe Photoshop Elements, version 10). Digitising 
software (ImageJ 1.45, National Institutes of Health, USA) 
was used to measure  VLACSA.
Torque measurements
At six different knee angles [60°, 65°, 70°, 75°, 80° and 
90° (full extension = 0°)], participants were instructed to 
perform two  MVCKE lasting ~2 s at the plateau, with 90 s 
rest between contractions. Torque was presented, in real-
time, on a Macintosh G4 computer (Apple Inc., Cupertino, 
CA, USA), via an A/D converter (Biopac Systems, Santa 
Barbara, CA, USA). Torque measurements were later ana-
lysed offline with the accompanying software (Acknowl-
edge, version 3.9.2). The highest peak torque produced at 
each angle was taken as  MVCKE peak torque. The knee 
angle where the highest torque was produced was recorded 
as optimal knee angle. In a randomised order,  MVCKE 
torque measurements were repeated at all six knee angles 
60 min post-eccentric exercise [to reduce any fatigue effect 
(Walsh et al. 2004)] and 48, 96 and 168 h post-eccentric 
exercise.  MVCKE torque loss was calculated from optimal 
knee angle identified at pre-damage.
Patella tendon length and cross‑sectional area
A real-time B-mode ultrasound (AU5 Harmonic, Esaote 
Biomedica, Genoa, Italy) was used to measure patella 
tendon cross-sectional area and patella tendon length at 
a fixed 90° knee angle. The distance between the apex of 
the patella and the tibial tuberosity, marked using sagittal 
ultrasound images, was taken as patella tendon length. To 
measure patella tendon cross-sectional area, the ultrasound 
probe was placed in the transverse plane and images were 
captured at 25, 50, and 75% of patella tendon length. The 
images were later analysed offline using image analyses 
software, ImageJ (1.45, National Institutes of Health, USA) 
patella tendon cross-sectional area is presented as a mean 
of all three images (O’Brien et al. 2010).
Patella tendon stiffness
The participants were seated in the isokinetic dynamom-
eter, with the knee angle fixed at 90°, and were instructed 
to perform a ramped, isometric  MVCKE lasting ~5–6 s. 
Ramped  MVCKE torque and displacement of the patella 
tendon were synchronised using a 10-V square wave, sig-
nal generator. Patella tendon displacement was measured 
over two  MVCKE, once with the ultrasound probe posi-
tioned over the distal edge of the patella and on the sec-
ond contraction over the tibial tuberosity (Onambélé et al. 
2007), so that total displacement would be computed from 
the composite of proximal and distal patella motions (see 
below). Torque was presented on a Macintosh G4 com-
puter (Apple Inc., Cupertino, CA, USA), via an A/D con-
verter and subsequently analysed with the accompanying 
software (Acknowledge, Biopac Systems, Santa Barbara, 
CA, USA). To create an external marker on the ultrasound 
images, an echo-absorptive marker was placed on the skin. 
Using the marker to calculate displacement, the distance 
of the marker (shadow) from an anatomical reference 
point at the beginning of the contraction to the position of 
the shadow at the end of the contraction was calculated. 
A square wave, signal generator was used to synchronise 
the ultrasound images with the torque acquisition system. 
Images were captured at ~10% intervals of ramped  MVCKE 
torque (Onambélé et al. 2007). Total patella tendon dis-
placement was calculated as displacement at the apex of the 
patella plus the displacement at the tibial tuberosity (Onam-
bélé et al. 2007). Patella tendon forces were calculated as: 
 (MVCKE torque + antagonist co-activation torque)/patella 
tendon moment arm.
Patella tendon moment arm was measured at 90° (full 
extension = 0°) in the sagittal plane, from a dual-energy 
X-ray absorptiometry scan (frame 23.3 cm × 13.7 cm, 
Hologic Discovery, Vertec Scientific Ltd, UK), and subse-
quently analysed using a DICOM image assessment tool 
(OsiriX DICOM viewer, ver. 4.0, Pixemo, Switzerland). 
Patella tendon moment arm length was determined as the 
perpendicular distance from the centre of the patella ten-
don to the tibio–femoral contact point. Dual-energy X-ray 
absorptiometry scans have recently been shown to be a reli-
able and valid method of measuring patella tendon moment 
arm length when compared to the gold standard method 
(MRI) (Erskine et al. 2014).
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For the calculation of tendon force, the calculation of 
antagonist co-activation torque is described below. The 
patella tendon force–elongation curve constructed from 
data analysed at every 10%  MVCKE, was then fitted with 
a second-order polynomial function forced through zero 
(Onambélé et al. 2007). The tangential slope at discreet 
sections of the curve, relative to  MVCKE force, was calcu-
lated by differentiating the curve at every 10% patella ten-
don force interval. In addition, to standardise the compari-
son of patella tendon stiffness at an absolute load, the slope 
of the tangential line, corresponding to the  MVCKE force 
of the weakest participant, was computed for each subject.
Co‑activation during maximal voluntary isometric knee 
extension
In order to compute patella tendon force, the co-activation 
of the biceps femoris during  MVCKE was measured. To 
determine co-activation of the biceps femoris during the 
ramped  MVCKE, electrodes (Ambu, Neuroline 720, Den-
mark) were placed in a bipolar configuration at 25% of 
biceps femoris muscle length (distal end = 0%). A refer-
ence electrode (Ambu, Blue Sensor, Denmark) was placed 
on the lateral tibial condyle. The raw electromyography 
signal was amplified (×2000) and filtered (through low 
and high pass filters of 10 and 500 Hz, respectively, notch 
at 50 Hz) with the sampling frequency set at 2000 Hz. 
Ramped  MVCKE torque and biceps femoris electromyo-
graphy were recorded in real-time and synchronised using 
a (10-V) square wave signal generator. Participants per-
formed two maximal voluntary isometric knee flexions 
 (MVCKF) at 90°. They were instructed to perform  MVCKF 
rapidly and as forcefully as possible and instructed to relax 
once a 2-s plateau had been attained (as observed on the 
dynamometer screen display). The root mean square of 
the biceps femoris electromyography signal was calcu-
lated 500 ms either side of instantaneous  MVCKF maximal 
torque from the contraction corresponding to the highest 
 MVCKF torque. Prior to contraction the baseline signal 
noise was calculated as the integral root mean square over 
1 s and removed from the measured electromyography dur-
ing  MVCKF and  MVCKE. At every 10% of ramped  MVCKE 
torque the absolute integral of the biceps femoris electro-
myography was taken over 250 ms. Co-activation torque 
was calculated as: (biceps femoris electromyography dur-
ing ramped  MVCKE/biceps femoris electromyography dur-
ing  MVCKF) × MVCKF torque at 90° knee angle (Onam-
bélé et al. 2007). This equation assumes that the biceps 
femoris is representative of the entire hamstring (Carolan 
and Cafarelli 1992) and that a linear relationship exists 
between biceps femoris electromyography and  MVCKF 
torque (Lippold 1952).
Patella tendon stress/strain relationship
Patella tendon strain was calculated as a ratio of total 
patella tendon displacement and patella tendon length. 
Patella tendon stress was calculated as: patella tendon force 
(N)/patella tendon cross-sectional area  (mm2).
Young’s modulus
Young’s modulus was calculated as: patella tendon stiff-
ness × [patella tendon length (mm)/patella tendon cross-
sectional area  (mm2)].
‘Damaging’ eccentric exercise
The damaging protocol used within the study has been 
described in detail previously (Hicks et al. 2013). Following 
a warm-up of 10 isokinetic knee extensions and knee flex-
ions, participants performed six sets of 12  MVEKE. For the 
eccentric exercise, the knee extension range of motion was 
set at 20°–90° (0° = full extension). The eccentric phase 
of the contractions was performed at an isokinetic angu-
lar velocity of 30°/s (Jamurtas et al. 2005). The concen-
tric phase was performed passively at an angular velocity 
of 60°/s. Two minutes rest was provided between each set. 
Participants remained seated in the isokinetic dynamom-
eter throughout the entire exercise protocol, including rest 
periods. Visual feedback and verbal encouragement were 
continuously provided throughout the protocol.  MVEKE 
torque was recorded throughout each contraction and dis-
played via the torque acquisition system. For each set, peak 
 MVEKE torque was determined as the highest torque out of 
the 12 repetitions. Average peak  MVEKE torque was calcu-
lated as an average of peak  MVEKE across six sets.
Muscle soreness
Muscle soreness was measured using a visual analogue 
scale. The visual analogue scale consisted of a 100 mm line, 
with 0 mm labelled “No pain at all” and 100 mm labelled 
“Unbearable pain”. Seated in the isokinetic dynamometer, 
the leg was passively moved through a full range of motion 
at 30°/s. Participants were asked to mark a line perpendicu-
lar to the visual analogue scale to denote the level of pain 
they experienced during the passive movement. The visual 
analogue scale has been reported to be a reliable measure 
of muscle soreness [ICC > 0.96 (Bijur et al. 2001)].
Blood samples
Venous blood samples were taken to measure CK and 
oestradiol levels. A 21-gauge needle was inserted into 
the antecubital vein of the forearm using a 10 ml syringe. 
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5–6 ml of blood was drawn into a serum collection tube. 
The sample was left on a crushed ice bed for 60 min. 
The sample was then centrifuged at 4500 rpm at 0 °C for 
10 min. Using a 200–1000 µl pipette (Eppendorf, Ham-
burg, Germany), the resulting serum sample was separated 
into three aliquots (~500 µl each) and stored in eppendorfs 
at −20 °C until CK and oestradiol analysis was performed.
Creatine kinase levels were measured using a standard 
colorimetry procedure, measuring at optical density 340 nm 
(BioTek ELx800 96 well Microplate Reader) and immedi-
ately analysed (Gen5, version 2.0). Each sample was run 
in duplicate-quadruplets using an  EnzyChromTM CK Assay 
Kit (BioAssay Systems, Hayward, CA, USA, sensitivity 
5 U/l, manufacturer intra-assay variability ≤5%). An aver-
age of 2–4 readings were taken. Creatine kinase activity 
is reported in two ways, firstly as absolute values and sec-
ondly, as the increase from pre to peak CK over the 168 h 
[(ΔCKpeak), i.e. the peak CK value − the pre-CK values].
Oestradiol was measured using a standard enzyme-
linked immunosorbent assay (ELISA) procedure (Alpha 
Diagnostic International, San Antonio, USA). Absorb-
ance was measured at optical density of 450 nm (BioTek 
ELx800 96 well Microplate Reader). The minimal oestra-
diol detection was ~10 pg/ml, the manufacturers intra-pre-
cision and inter-precision was 9.85 and 10.3%, respectively. 
To calculate oestrogen levels, a standard curve was plotted 
using the six standards against their absorbance. Using the 
mean absorbance of each sample, the concentration of the 
sample was read directly from the standard curve.
Statistics
Statistical analyses were carried out using the statistical 
software package SPSS (v.19, Chicago, IL, USA) for Win-
dows and Microsoft Excel. To ensure that the data were 
parametric, the Levene’s and Shapiro–Wilk’s tests were 
used to assess the variance and normality of the data. If 
parametric tests were violated, the equivalent non-paramet-
ric tests were used. For group differences in anthropometric 
measures, oestrogen levels,  VLACSA, patella tendon proper-
ties, and ΔCKpeak independent T tests were used. A 2 × 5 
mixed design analysis of variance [ANOVA, between fac-
tors: OCP use (2 levels) and time from EIMD (5 levels)] 
was used for muscle soreness,  MVCKE torque loss and CK 
levels. Wherever the assumption of sphericity was violated, 
the Greenhouse–Geisser correction was used. When a sig-
nificant group effect was found a planned contrast, with 
LSD correction, was used to identify where the significant 
difference lay. Since an association was reported between 
age and  MVCKE torque loss, an analysis of covariance was 
used. For the variables being investigated as a potential 
determinant of EIMD, confidence levels and Cohen d were 
calculated. Significance was set at p ≤ 0.05. The data are 
presented as mean ± standard deviation.
Results
Anthropometric measurements
OCP users were significantly older by 2.2 years (p = 0.010) 
and of an 11% greater mass (p = 0.047) than non-users. 
There was no significant difference in stature between OCP 
users and non-users (p = 0.061).
Oestrogen levels
Serum oestrogen levels were significantly lower in OCP 
users compared to non-users on the 14th day of the cycle 
(pill or menstrual) (209 ± 115 and 433 ± 147 pg/ml, 
respectively, p = 0.004).
VLACSA
There was no significant difference in  VLACSA 
between OCP users and non-users (21.9 ± 2.64 and 
20.1 ± 3.40 cm2, respectively, p = 0.224).
Tendon properties
Patella tendon properties for OCP users and non-users are 
presented in Table 1. Patella tendon length, patella tendon 
cross-sectional area and patella tendon moment arm were 
not significantly different between OCP users and non-
users (p ≥ 0.05). Furthermore, ramped  MVCKE torque and 
patella tendon force were not significantly different between 
OCP users and non-users (p ≥ 0.05). Patella tendon elon-
gation was not significantly different between OCP users 
and non-users (7.20 ± 1.30, 8.16 ± 0.80 mm, respectively, 
p = 0.075). Tendon stiffness (Fig. 2) at  MVCKE was not 
Table 1  Patella tendon properties in OCP users and non-users
Patella tendon stiffness and Young’s modulus are presented at 100% 
ramped maximal voluntary isometric knee extension. Patella tendon 
moment arm was measured at 90° knee angle
OCP users Non-users
Patella tendon length (mm) 52.9 ± 4.3 49.0 ± 6.0
Mean patella tendon cross-sectional area 
 (mm2)
63.2 ± 15.1 56.0 ± 17.2
Patella tendon moment arm (cm)  4.01 ± 0.24 3.96 ± 0.28
Maximal ramped  MVCKE torque (Nm) 143 ± 30 132 ± 27
Maximal patella tendon force (N) 3634 ± 717 3430 ± 768
Maximal patella tendon stiffness (N/mm) 872 ± 366 665 ± 169
Maximal Young’s modulus (MPa) 761 ± 331 642 ± 285
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significantly different between OCP users and non-users 
[p = 0.153, CI (−502, 88.0), d = 0.73]. Young’s modulus 
was not significantly different between OCP users and non-
users [p = 0.213, CI (−190, 428), d = 0.38]. Patella tendon 
stiffness calculated at a standardised patella tendon force 
(2330 N) was not significantly different between OCP users 
and non-users (725 ± 219 and 565 ± 103 N/mm, respec-
tively [p = 0.070, CI (−10.9, 331), d = 0.94]. Patella tendon 
Young’s modulus calculated at a standardised patella ten-
don force (2330 N) was not significantly different between 
OCP users and non-users [628 ± 219 and 536 ± 190 MPa, 
respectively (p = 0.175 CI (−111, 298), d = 0.453)].
Torque production during  MVEKE
There was no significant difference in the average peak 
 MVEKE torque of each set (six in total) between OCP 
users and non-users (p ≤ 0.05). There was no significant 
difference in the average peak  MVEKE torque (averaged 
over 6 sets) between OCP users and non-users (182 ± 33 
and 167 ± 32 Nm, respectively, p = 0.093). Peak  MVEKE 
torque made relative to pre-MVCKE torque was sig-
nificantly higher in OCP users compared to non-users 
(108 ± 16.7 and 85.0 ± 11.9%, respectively, p = 0.002).
Change in optimal knee angle
Pre-damage, optimal  MVCKE knee angle was not signifi-
cantly different between OCP users and non-users (median, 
75.0 ± 7.0°, and 75.0 ± 7.0°, respectively, p = 0.430). 
Post-EIMD both OCP users (80.0 ± 7.0°, p = 0.010) and 
non-users (median 80.0 ± 7.0°, p = 0.030) demonstrated a 
significant rightward shift in  MVCKE optimal angle. There 
was no significant difference in the magnitude of the right-
ward shift in  MVCKE optimal angle between OCP users 
and non-users (p = 0.311).
MVCKE torque loss
MVCKE torque loss expressed as a percentage of pre-
damage  MVCKE torque is illustrated in Fig. 3. A two-
way repeated mixed ANOVA for  MVCKE torque loss 
post-EIMD, reported a significant main effect of time 
(p = 0.0004); however, no group effect (OCP users versus 
non-users p = 0.257) nor interaction (times versus group, 
p = 0.118) was reported. Pre-MVCKE peak torque was not 
significantly different between OCP users and non-users 
(169 ± 24.3 and 194 ± 36.2 Nm, p = 0.055). Although a 
significant tendency was reported, peak  MVCKE torque loss 
made relative to pre-damage  MVCKE torque was not signif-
icantly different between OCP users compared to non-users 
(17 ± 7 and 28 ± 13%, respectively [p = 0.055, CI (−21.5, 
10.5), d = 0.94)].
A significant correlation was observed between age 
and  MVCKE torque loss (r = 0.58, p = 0.011). Age was 
therefore considered as a covariate of  MVCKE torque loss. 
A subsequent ANCOVA revealed that no significant differ-
ence in  MVCKE torque loss between OCP users and non-
users remained when age was accounted for (p = 0.179).
Creatine kinase levels
A two-way repeated mixed ANOVA for CK reported a sig-
nificant main effect of time (p = 0.040); however, no sig-
nificant group (OCP users versus non-users, p = 0.057) 
or interaction (time versus group, p = 0.576) effects were 
reported (Fig. 4). ΔCKpeak was significantly higher in OCP 
users compared to non-users over the 168 h [962 ± 968 and 
Fig. 2  Patella tendon force–elongation relationship, during ramped 
maximal voluntary isometric contraction, in oral contraceptive pill 
user and non-users. Data are presented as mean ± standard deviation
Fig. 3  Maximal voluntary isometric knee extensor torque in oral 
contraceptive pill users and non-users expressed as a percentage of 
maximal voluntary isometric knee extensor torque pre-damage. Data 
are presented as mean ± standard deviation
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386 ± 474 UL, respectively (p = 0.016, CI (−186, 1338), 
d = 0.76)].
Muscle soreness
A two-way mixed measures ANOVA for muscle soreness 
reported a significant main effect of time (p = 0.0004); 
however, there was no significant group difference (OCP 
users versus non-users, p = 0.598) or an interaction effect 
(p = 0.127). For both OCP users and non-users peak mus-
cle soreness occurred 48 h post-EIMD. There was no sig-
nificant difference in peak muscle soreness between OCP 
users and non-users (40 ± 3 mm and 41 ± 1 mm, respec-
tively, p = 0.358).
Discussion
The current study found that (1) the CK response was aug-
mented in OCP users compared to non-users; however, 
 MVCKE torque loss and muscle soreness were not different; 
(2) the patella tendon properties were not significantly dif-
ferent between the OCP users and non-users and, as such, 
did not contribute to the observed significant difference in 
EIMD.
Within the current study, the circulating oestrogen levels 
within the OCP users were 2.8 times higher than oestrogen 
levels within OCP users reported by Bryant et al. (2008). 
This discrepancy in oestrogen levels may be confounded 
by a secondary rise in oestrogen levels following the pill-
free interval period within the current study. Despite ele-
vated levels within OCP users, in agreement with previous 
research (Bryant et al. 2008), the current study confirms a 
significant down regulation of oestrogen within OCP users 
compared to non-users. Thus it is reasonable to assume that 
in the present study, the down regulation of oestrogen in the 
OCP users compared to the non-users and the suppression 
of oestrogen in the OCP users, remained throughout the 
cycle (Bryant et al. 2008).
Due to high levels of oestrogen attenuating circulating 
levels of IGF-I (Heald et al. 2005) it can be expected that 
the anabolic effect of IGF-I on tendon fibroblast and there-
fore tendon collagen synthesis is greater in OCP users com-
pared to non-users. Subsequently, higher tendon stiffness in 
OCP users compared to non-user may be expected. Within 
the current study, however, despite significantly lower oes-
trogen levels in OCP users, there was no significant differ-
ence in patella tendon stiffness in vivo between OCP users 
and non-users. Although our data show a trend towards 
higher stiffness in the OCP users, our findings did not reach 
significance and contradict those of Bryant et al. (2008), but 
are in agreement with those of Hansen et al. (2013). Bryant 
et al. (2008) concluded that exposure to the OCP (≥1 year) 
decreases Achilles tendon strain properties. These discrep-
ancies may be attributed to the fact that Bryant et al. (2008) 
reported data from the Achilles tendon, whereas the present 
study assessed the patella tendon. Therefore, it is possible 
that the Achilles and patella tendons show inconsistent 
responses to the OCP due to the difference in the number of 
oestrogen receptor sites, as our findings concur with those 
of Hansen et al. (2013). Hansen et al. (2013) reported no 
significant difference in patella tendon stiffness or Young’s 
modulus between OCP users and non-users. The current 
study confirms that the OCP does not alter patella tendon 
stiffness or Young’s modulus in recreationally active par-
ticipants. The conclusion that the OCP has no significant 
effect on tendon properties, specifically patella tendon 
stiffness, may discount any potential differences in EIMD 
between OCP users and non-users being directly attributed 
to patella tendon properties.
As a marker of muscle damage, the current study 
reported no significant difference in  MVCKE torque loss 
between OCP users and non-users, which both supports 
(Sewright et al. 2008) and contradicts (Minahan et al. 2015; 
Savage and Clarkson 2002) previous research. Within the 
knee extensors, our findings directly contradict those of 
Minahan et al. (2015) who reported torque loss 48 h post-
EIMD to be significantly higher in OCP users compared to 
non-users. The discrepancies may be attributed to Minahan 
et al. (2015) reporting substantially lower levels of oestro-
gen in the OCP users compared to the current study. Differ-
ing levels of oestrogen may be explained by Minahan et al. 
(2015) measuring oestrogen during the 7 days pill-free 
period, whereas the current study measured oestrogen on 
the 14th day (7th pill day) and the mix of OCP brands used 
within both studies (Elliott-Sale et al. 2013). Although the 
current study tested on the 7th day of the pill cycle to try 
and avoid the secondary peak in oestrogen, testing on the 
Fig. 4  Creatine kinase response in oral contraceptive pill users and 
non-users pre (−48 h) and post-exercise induced muscle damage. 
Data are presented as mean ± standard deviation
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10th day of the pill cycle (Legro et al. 2008) and control-
ling the type of OCP used (Elliott-Sale et al. 2013) may be 
required to ensure OCP oestrogen levels are plateaued and 
comparable, respectively. Therefore, although a significant 
difference in oestrogen levels between OCP users and non-
users was reported within the current study, the augmented 
oestrogen levels within the OCP users when measured on 
day 7 of the pill cycle may have masked the effect of OCP 
use on torque loss post-EIMD. Therefore, the current study 
concludes that on the 14th day of the cycle (pill or men-
strual), there is no significant difference in  MVCKE torque 
loss between OCP users and non-users post-EIMD.
Although torque loss is regarded as the most functional 
measure of EIMD (Warren et al. 1999), in agreement with 
previous research (Joyce et al. 2014; Minahan et al. 2015; 
Roth et al. 2001), the current study reported ΔCKpeak to 
be significantly higher in OCP users (low oestrogen lev-
els) compared to non-users (high oestrogen levels) fol-
lowing EIMD. Although Joyce et al. (2014) and Minahan 
et al. (2015) reported CK levels to be significantly higher in 
OCP users compared to non-users, they only monitored CK 
up to 48 h post-EIMD despite peak CK characteristically 
occurring at 96 h post-EIMD (Hyatt and Clarkson 1998). 
By measuring CK at 96 and 168 h post-EIMD, the current 
study reduces the chance of missing a true peak in CK and 
can therefore confirm that ΔCKpeak is significantly higher 
in OCP users compared to non-users post-EIMD. In appar-
ent contrast to our findings, 72 h post-EIMD, Carter et al. 
(2001) observed OCP users to have significantly lower CK 
levels compared to non-users. It should be noted, however, 
that we carried out EIMD on day 14 of the menstrual cycle, 
whereas Carter et al. (2001) carried out EIMD on day 22 
(midluteal phase). In the present study, we observed oestro-
gen levels to be significantly lower in OCP users compared 
to non-users, whereas Carter et al. (2001) showed OCP 
users to higher oestrogen levels compared to non-users. 
Ignoring the OCP status of Carter et al. (2001) participants, 
at the time of testing, the group with the lowest oestrogen 
level showed significantly higher CK levels post-EIMD. 
This is therefore consistent with our findings, that the lower 
oestrogen levels (observed within our OCP users) results in 
a higher ΔCKpeak post-EIMD.
Oestrogen has been reported to decrease cell membrane 
fluidity, thus increase cell membrane stability. An increase 
in cell membrane stability may prevent muscle proteins 
(i.e. CK) leaking into the interstitial space and into the 
systemic circulation (Carter et al. 2001; Wiseman et al. 
1993) and attenuate the influx of neutrophils and cytokines 
post-EIMD (MacNeil et al. 2011; Silvestri et al. 2003). In 
support of oestrogen preventing the leakage of CK from 
the intracellular membrane, Carter et al. (2001) reported 
a moderate correlation (r = −0.43, p < 0.05) between 
total resting oestrogen levels and overall CK. Therefore, 
the potential effects of oestrogen on cell membrane sta-
bility may explain the differences in CK levels between 
OCP users and non-users within the current study; how-
ever, muscle biopsies would be required to confirm such 
conclusions.
Although the current study controlled for the type 
(monophasic) and the dosage of synthetic oestrogen level 
within the OCP, it must be noted that the oestrogen levels 
vary between different brands of OCP (Elliott et al. 2005). 
Therefore, to fully understand the effect of OCP on EIMD, 
a specific brand needs to be investigated. Furthermore, due 
to the natural fluctuation of oestrogen levels during the 
menstrual cycle and the repeated measure design of the 
current study, measurement of oestrogen levels at every 
time point, rather than just on day 14 of the menstrual 
cycle, may be required in future studies.
As no other significant differences between suggested 
determinants of EIMD in OCP users and non-users (tendon 
properties and  MVEKE torque) have been reported, the cur-
rent study concludes that the higher ΔCKpeak in OCP users 
may be attributed to the significantly higher oestrogen lev-
els in non-users. Therefore, the current study concludes 
that OCP use does not increase susceptibility to functional 
impairment  (MVCKE torque loss) post-EIMD, but it does 
augment the CK response post-EIMD.
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